Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 163,600 shares, an increase of 164.3% from the September 30th total of 61,900 shares. Based on an average daily volume of 1,000,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 5.7% of the company’s stock are short sold.
Processa Pharmaceuticals Trading Up 0.8 %
PCSA stock opened at $1.31 on Friday. Processa Pharmaceuticals has a 12-month low of $1.19 and a 12-month high of $17.40. The stock’s 50 day simple moving average is $1.36 and its 200 day simple moving average is $1.67. The stock has a market capitalization of $4.27 million, a PE ratio of -0.33 and a beta of 0.59.
Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.03). On average, research analysts predict that Processa Pharmaceuticals will post -3.78 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Processa Pharmaceuticals
About Processa Pharmaceuticals
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
See Also
- Five stocks we like better than Processa Pharmaceuticals
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 10/21- 10/25
- How to Calculate Return on Investment (ROI)
- Texas Roadhouse Stock Steering for New Highs This Year
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.